| Literature DB >> 31220119 |
Jamie L Almeida1, Aleksandra Dakic2, Karin Kindig2, Maikan Kone2, Deborah L D Letham3, Scott Langdon4, Ruth Peat5, Jayamalini Holding-Pillai5, Erin M Hall6, Mark Ladd6, Megan D Shaffer6, Heath Berg7, Jinliang Li8, Georges Wigger9, Steve Lund10, Carolyn R Steffen11, Barbara B Fransway12, Bob Geraghty13, Manuela Natoli13, Beth Bauer14, Susanne M Gollin15, Dale W Lewis15, Yvonne Reid1.
Abstract
The Consortium for Mouse Cell Line Authentication was formed to validate Short Tandem Repeat (STR) markers for intraspecies identification of mouse cell lines. The STR profiling method is a multiplex polymerase chain reaction (PCR) assay comprised of primers targeting 19 mouse STR markers and two human STR markers (for interspecies contamination screening). The goals of the Consortium were to perform an interlaboratory study to-(1) validate the mouse STR markers to uniquely identify mouse cell lines (intraspecies identification), (2) to provide a public database of mouse cell lines with the National Institute of Standards and Technology (NIST)-validated mouse STR profiles, and (3) to publish the results of the interlaboratory study. The interlaboratory study was an international effort that consisted of 12 participating laboratories representing institutions from academia, industry, biological resource centers, and government. The study was based on 50 of the most commonly used mouse cell lines obtained from the American Type Culture Collection (ATCC). Of the 50 mouse cell lines, 18 had unique STR profiles that were 100% concordant (match) among all Consortium laboratory members, and the remaining 32 cell lines had discordance that was resolved readily and led to improvement of the assay. The discordance was due to low signal and interpretation issues involving artifacts and genotyping errors. Although the total number of discordant STR profiles was relatively high in this study, the percent of labs agreeing on allele calls among the discordant samples was above 92%. The STR profiles, including electropherogram images, for NIST-validated mouse cell lines will be published on the NCBI BioSample Database (https://www.ncbi.nlm.nih.gov/biosample/). Overall, the interlaboratory study showed that the multiplex PCR method using 18 of the 19 mouse STR markers is capable of discriminating at the intraspecies level between mouse cell lines. Further studies are ongoing to refine the assay including (1) development of an allelic ladder for improving the accuracy of allele calling and (2) integration of stutter filters to identify true stutter.Entities:
Mesh:
Year: 2019 PMID: 31220119 PMCID: PMC6586308 DOI: 10.1371/journal.pone.0218412
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Consortium laboratory members.
| Affiliation | Institution | Country |
|---|---|---|
| ATCC | Cell Bank | USA |
| Charles River Laboratories | Industry | USA |
| Duke University | Academia | USA |
| Francis Crick Institute | Academia | UK |
| Genetica Cell Line Testing | Industry | USA |
| IDEXX BioAnalytics | Industry | USA |
| Laragen Inc. | Industry | USA |
| Microsynth AG | Industry | Switzerland |
| NIST | Government | USA |
| University of Arizona | Academia | USA |
| University of Cambridge | Academia | UK |
| University of Pittsburgh | Academia | USA |
Fig 1Stutter ratios calculated from diploid mouse DNA samples.
Each marker with associated stutter ratios for the represented alleles is plotted here. The y-axis is the observed percent stutter ratio and x-axis shows the allele number (number of repeats).
Fig 2Normalizing stutter across alleles.
The y-axis shows each observed stutter ratio divided by the average of all stutter ratios observed for the same marker and allele. The x-axis shows the allele number (number of repeats).
Fig 3Summary of the effect of instrument on stutter ratio across markers.
The combination across the 19 STR markers and relative position for each of the instruments is condensed into a single plot. Each line corresponds to a particular marker, where the four points on each line denote the respective average normalized stutter ratios within that STR marker for the four instruments.
Marker-specific stutter filter recommendations.
| STR Marker | Known Allele Range | Stutter Ratio (%) | Allele Range Represented in Stutter Ratio Calculation |
|---|---|---|---|
| 18–3 | 13–28 | 20.52 | 16–23 |
| 4–2 | 13–23.3 | 13.80 | 16.3–22.3 |
| 11–1 | 17–23.3 | 19.75 | 17.3–23.3 |
| 6–7 | 11–26 | 16.13 | 12–26 |
| 19–2 | 10–16 | 11.77 | 10–16 |
| 1–2 | 12–30.1 | 13.20 | 13–22 |
| 7–1 | 19.2–33.2 | 12.98 | 24.2–33.2 |
| 1–1 | 10–19 | 13.71 | 10–20 |
| 3–2 | 9–25 | 16.07 | 9–25 |
| 8–1 | 6–19 | 18.12 | 6–18.3 |
| 2–1 | 8–17.1 | 17.71 | 9–16 |
| 15–3 | 12–31.3 | 19.03 | 18.3–27.3 |
| 6–4 | 12.2–21 | 12.16 | 15.3–21 |
| 11–2 | 12–26.2 | 17.16 | 15–26.2 |
| 17–2 | 11–22 | 16.98 | 12–22 |
| 12–1 | 15–24.1 | 11.90 | 15–23 |
| 5–5 | 11–22 | 13.72 | 11–21 |
| X-1 | 15.2–37 | 18.74 | 21–37 |
| 13–1 | 11–20.1 | 22.60 | 11–20.1 |
Consortium laboratory member instrument, polymer, array, and software used in the interlaboratory study.
| Group | Instrument | Array | Polymer | Software |
|---|---|---|---|---|
| 1 | ABI 3130xl | 36 cm | POP-4 | GeneMapper v5.0 |
| 2 | ABI 3130xl | 50 cm | POP-7 | GeneMapper v5.0 |
| 3 | ABI 3130xl | 36 cm | POP-4 | GeneMapper ID v3.2.1 |
| 4 | ABI 3130xl | 50 cm | POP-7 | GeneMapper v5.0 |
| 5 | ABI 3730xl | 50 cm | POP-7 | GeneMapper 4.0 |
| 6 | ABI 3130xl | 36 cm | POP-4 | GeneMapper v4.0 |
| 7 | ABI 3730xl | 50 cm | POP-7 | GeneMapper v4.0, v5.0 |
| 8 | ABI 3730xl | 50 cm | POP-7 | Gene Marker v2.7.6 |
| 9 | ABI 3130xl | 36 cm | POP-4 | GeneMapper v4.1, v5.0 |
| 10 | ABI 3730 | 36 cm | POP-7 | GeneMarker v1.85, v2.6.3 |
| 11 | ABI 3500xl | 50 cm | POP-7 | GeneMapper ID-X v1.2 |
| 12 | ABI 3500xl | 36 cm | POP-4 | GeneMapper ID-X v1.3 |
Parameters for capillary electrophoresis for each group.
| Group | CE Parameters |
|---|---|
Fig 4Peak morphology of STR marker 11–1.
A. Arrow denotes irregular peak morphology of allele 19 from diploid DNA from an AKR mouse (Jackson Laboratories). B. Arrow denotes irregular peak morphology of allele 19 from the JC cancer cell line. C. Normal peak morphology of allele 20.3 from diploid DNA from C58 mouse (Jackson Laboratories). D. Normal peak morphology of allele 20.3 from the CMT-93 cancer cell line. E. Arrows denote irregular peak morphology of allele 19 from the CT26.CL25 cancer cell line.
Discordant NIH/3T3 cell line.
| STR Markers | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18–3 | 4–2 | 6–7 | 19–2 | 1–2 | 7–1 | 1–1 | 3–2 | 8–1 | 2–1 | 15–3 | 6–4 | 11–2 | 17–2 | 12–1 | 5–5 | X-1 | 13–1 | |
| Lab | Consortium Laboratory Member Allele Calls | |||||||||||||||||
| 1 | 17,19 | 19.3, 20.3 | 12 | 11,12 | 13,17 | 29 | 10 | 14,15 | 15 | 9 | 20.3 | 15.3 | 15,17 | 13,14 | 20 | 14,15 | 25 | 16.2 |
| 2 | 17,19 | 19.3, 20.3 | 12 | 11,12 | 13,17 | 29 | 10 | 14,15 | 15 | 9 | 20.3 | 15.3 | 15,17 | 13,14 | 20 | 14,15 | 25 | 16.2 |
| 3 | 17,19 | 19.3, 20.3 | 12 | 11,12 | 13,17 | 29 | 10 | 14,15 | 15 | 9 | 20.3 | 15.3 | 15,17 | 13,14 | 20 | 14,15 | 25 | 16.2 |
| 4 | 17,19 | 19.3 | 12 | 11,12 | 13,17 | 29 | 10 | 14,15 | 15 | 9 | 20.3 | 15.3 | 15,17 | 13,14 | 20 | 14,15 | 25 | 16.2 |
| 5 | 17,19 | 19.3, 20.3 | 12 | 11,12 | 13,17 | 29 | 10 | 14,15 | 15 | 9 | 20.3 | 15.3 | 15,17 | 13,14 | 20 | 14,15 | 25 | 16.2 |
| 6 | 17,19 | 19.3, 20.3 | 12 | 11,12 | 13,17 | 29 | 10 | 14,15 | 15 | 9 | 20.3 | 15.3 | 15,17 | 13,14 | 20 | 14,15 | 25 | 16.2 |
| 7 | 17,19 | 19.3, 20.3 | 12 | 11,12 | 13,17 | 29 | 10 | 14,15 | 15 | 9 | 20.3 | 15.3 | 15,17 | 13,14 | 20 | 14,15 | 25 | 16.2 |
| 8 | 17,19 | 19.3, 20.3 | 12 | 11,12 | 13,17 | 29 | 10 | 14,15 | 15 | 9 | 20.3 | 15.3 | 15,17 | 13,14 | 20 | 14,15 | 25 | 16.2 |
| 9 | 17,19 | 19.3, 20.3 | 12 | 11,12 | 13,17 | 29 | 10 | 14,15 | 15 | 9 | 20.3 | 15.3 | 15,17 | 13,14 | 20 | 14,15 | 25 | 16.2 |
| 10 | 17,19 | 19.3, 20.3 | 12 | 11,12 | 13,17 | 29 | 10 | 14,15 | 15 | 9 | 20.3 | 15.3 | 15,17 | 13,14 | 20 | 14,15 | 25 | 16.2 |
| 11 | 17,19 | 19.3, 20.3 | 12 | 11,12 | 13,17 | 29 | 10 | 14,15 | 15 | 9 | 20.3 | 15.3 | 15,17 | 13,14 | 20 | 14,15 | 25 | 16.2 |
| 12 | 17,19 | 19.3, 20.3 | 12 | 11,12 | 13,17 | 29 | 10 | 14,15 | 15 | 9 | 20.3 | 15.3 | 15,17 | 13,14 | 20 | 14,15 | 25 | 16.2 |
Concordant STR profiles for 21 mouse cell lines.
| Cell Lines | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STR Marker | NCTC clone 929 | BALB/ 3T3 clone A31 | L1210 | CMT-93 | STO | NMuMG | P19 | M-NFS-60 | Hepa-1c1c7 | M-1 | JC | WEHI-13VAR | RAW 264.7 gamma NO- | EOC 20 | EMT6 | YAC-1 | M1 | BCL1 clone 5B1b | 2E8 | J558 | RAW 264.7 |
| Alleles | |||||||||||||||||||||
| 18–3 | 16 | 18 | 16,17 | 16 | 19 | 18 | 16,17 | 17 | 16,17 | 17 | 18,19 | 17,18 | 18 | 16 | 18,19 | 18 | 18 | 18,19 | 18 | 18 | 18 |
| 4–2 | 20.3 | 21.3 | 20.3 | 20.3 | 20.3 | 20.3 | 13,21.3 | 19.3,20.3 | 18.3,19.3 | 20.3 | 21.3 | 21.3,22.3 | 22.3,23.3 | 19.3 | 21.3 | 21.3 | 20.3 | 21.3 | 21.3 | 21.3 | 22.3 |
| 6–7 | 12 | 12 | 12 | 15 | 12 | 15 | 12 | 12 | 15 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 16 | 12 | 12 | 12 | 12 |
| 19–2 | 12 | 14 | 12 | 14 | 12 | 12 | 12,14 | 11,12 | 10,11 | 13 | 14 | 13 | 12,14 | 12 | 13 | 12,13 | 13,14 | 12,13 | 14 | 14 | 14 |
| 1–2 | 17 | 17 | 16 | 19,20 | 16 | 17 | 16,17 | 17 | 13 | 19 | 17,18 | 17 | 17 | 16 | 17,18 | 17,18 | 13 | 17 | 17 | 17 | 17 |
| 7–1 | 25,26,27 | 25.2 | 27,28 | 26.2 | 25.2 | 25.2 | 26 | 28,29 | 25.2 | 26.2 | 24.2 | 25.2 | 25.2 | 26 | 25.2 | 25.2 | 25.2 | 26.2 | 24.2 | 25.2 | 25.2 |
| 1–1 | 10 | 16 | 15,17 | 15 | 12 | 15, 16 | 10 | 10,16 | 14,15 | 17 | 14 | 15 | 15,16 | 10 | 15 | 11 | 16 | 14 | 15 | 16 | 15,16 |
| 3–2 | 13,14 | 14 | 13 | 14 | 14 | 14 | 14 | 13,14 | 10 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 12 | 14 | 14 | 14 | 14 |
| 8–1 | 16 | 13 | 16 | 16 | 16 | 16 | 16 | 15,16 | 15 | 16 | 13 | 13 | 13 | 16,17 | 13 | 16 | 16,17 | 13 | 13 | 13 | 13 |
| 2–1 | 9 | 16 | 15 | 16 | 9 | 15, 16 | 9 | 9,16 | 14 | 9,16 | 16 | 16,17 | 16 | 9 | 16 | 16 | 9 | 15 | 16 | 16 | 16 |
| 15–3 | 24.3,25.3,26.3 | 22.3 | 21.3,22.3 | 22.3 | 20.3 | 21.3, 22.3 | 26.3 | 20.3,21.3 | 17,18,19 | 22.3 | 22.3,23.3 | 22.3 | 22.3 | 25.3 | 22.3,23.3 | 22.3 | 22.3 | 22.3 | 23.3.24.3 | 22.3 | 22.3 |
| 6–4 | 17,18 | 18 | 17 | 18,19 | 15.3 | 17,18 | 18 | 15.3,18 | 18,19 | 15 | 18 | 18,19 | 18 | 19 | 18 | 18 | 16.3 | 18 | 17 | 18 | 18 |
| 11–2 | 15,16 | 17 | 17 | 16 | 15 | 15 | 16 | 17,19 | 16 | 16 | 17 | 17,18 | 17 | 17 | 18 | 15 | 15,16 | 18 | 16,17 | 17 | 17 |
| 17–2 | 15 | 15,16 | 16 | 15,16 | 13 | 16,17 | 15 | 13,15 | 14 | 15 | 16 | 16 | 14,16 | 16 | 16 | 16 | 12 | 15 | 17 | 16 | 14,16 |
| 12–1 | 16 | 16 | 16 | 17 | 19 | 16 | 16 | 16,20 | 17,18 | 17 | 16 | 16 | 16,17 | 16 | 16 | 16 | 16,17 | 16 | 16 | 16 | 16 |
| 5–5 | 14 | 14 | 13 | 14,16,17 | 14 | 15 | 14 | 14,15 | 17,18 | 17 | 14 | 13,14 | 14 | 15 | 13,15 | 16 | 14 | 13,14 | 14 | 14 | 14 |
| X-1 | 26,27 | 25 | 27 | 27 | 26 | 27,28 | 26 | 25,27 | 25 | 28 | 25 | 26 | 25 | 27 | 24 | 26 | 26 | 24,25 | 26 | 25 | 24 |
| 13–1 | 17 | 16.2 | 17 | 17 | 16.2 | 16.2,17 | 17 | 13,15.2 | 17.1 | 17 | 16.2 | 15.2 | 16.2 | 17 | 16.2 | 16.2,17.2 | 16.2 | 16.2 | 16.2 | 16.2 | 16.2 |
Summary of discordant cell line.
| At 18 Mouse STR Markers | |||
|---|---|---|---|
| Cell Line Name | Mean % Groups Agree on Allele Calls | Number of Markers Discordant | Reason(s) for Discordance |
| A9 | 0.989 | 2 | b |
| 3T3-Swiss Albino | 0.981 | 2 | a, d |
| P3X63Ag8.653 | 0.994 | 2 | b |
| Sp2/0-Ag14 | 0.984 | 4 | b, c, e |
| LL/2 (LLC1) | 0.991 | 4 | a, b, d, e |
| NIH/3T3 | 0.997 | 1 | b |
| McCoy B | 0.981 | 3 | a, b, d |
| WEHI 164 | 0.991 | 1 | c |
| Hepa 1–6 | 0.986 | 2 | a, b, e |
| HT-2 clone A5E | 0.953 | 7 | a, b, c |
| MLTC-1 | 0.993 | 1 | b |
| E.G7-OVA | 0.963 | 5 | b |
| mIMCD-3 | 0.985 | 2 | d |
| MS1 | 0.993 | 1 | b |
| 4T1 | 0.993 | 2 | b |
| W-20-17 | 0.997 | 1 | e |
| CT26.WT | 0.977 | 4 | b |
| CT26.CL25 | 0.990 | 2 | b |
| Renca | 0.997 | 1 | b |
| B16-F0 | 0.990 | 2 | b |
| B16-F1 | 0.995 | 2 | b |
| A20 | 0.992 | 1 | b |
| CTLL-2 | 0.991 | 1 | a |
| D10.G4.1 | 0.982 | 3 | b, e |
| EL4 | 0.963 | 5 | a, b, d |
| C1498 | 0.967 | 4 | b, c |
| P815 | 0.989 | 2 | a, b, c |
| Sarcoma 180 | 0.918 | 16 | a, b, c |
| WEHI-3 | 0.985 | 5 | b, c, e |
*Reasons for discordance are coded as follows: a. low fluorescent signal, b. error in calculation of stutter ratio, c. stutter ratio was at the stutter threshold, d. missed allele (not labeled), e. artifact (pull-up, dye blob, spike)
Percent matching of known related cell lines using Master’s algorithm.
| Parental Cell Line | Derivative of parental cell line | Percent Matching |
|---|---|---|
| NCTC clone 929 | A9 | 85% |
| WEHI 164 | WEHI-13VAR | 91% |
| CT26.WT | CT26.CL25 | 87% |
| B16-F0 | B16-F1 | 94% |
| RAW 264.7 | RAW 264.7 gamma NO- | 95% |
Cell lines used in the interlaboratory study.
| Code | ATCC# | Cell Line Designation | Mouse Strain | Tissue Type and/or Disease |
|---|---|---|---|---|
| M01 | CCL-1 | NCTC clone 929 | C3H/An | Subcutaneous connective tissue |
| M02 | CCL-1.4 | A9 | C3H/An | Subcutaneous connective tissue |
| M03 | CCL-163 | BALB/3T3 clone A31 | BALB/c | Embryo |
| M04 | CCL-219 | L1210 | DBA/2 | Lymphocytic leukemia |
| M05 | CCL-223 | CMT-93 | C57BL/icrf | Rectal, Polyploid carcinoma |
| M06 | CCL-92 | 3T3-Swiss albino | Swiss | Embryo |
| M07 | CRL-1503 | STO | SIM | Mouse embryonic fibroblasts |
| M08 | CRL-1580 | P3X63Ag8.653 | BALB/c | Plasmacytoma/Myeloma |
| M09 | CRL-1581 | Sp2/0-Ag14 | BALB/c | Spleen, Myeloma |
| M10 | CRL-1636 | NMuMG | NAMRU | Mammary gland |
| M11 | CRL-1642 | LL/2 (LLC1) | C57BL | Lewis Lung carcinoma |
| M12 | CRL-1658 | NIH/3T3 | Swiss | Embryo |
| M13 | CRL-1696 | McCoy (McCoy B) | C3H/An | Synovial fluid in the knee joint |
| M14 | CRL-1751 | WEHI 164 | BALB/c | Fibrosarcoma |
| M15 | CRL-1825 | P19 | C3H/He | Teratocarcinoma/Embryonal carcinoma |
| M16 | CRL-1830 | Hepa 1–6 | C57L | Liver, Hepatoma |
| M17 | CRL-1838 | M-NFS-60 | NFS/N (NFSxDBA/2) | Blood, Myelogenous leukemia |
| M18 | CRL-1841 | HT-2 clone A5E | BALB/c | Spleen |
| M19 | CRL-2026 | Hepa-1c1c7 | C57L | Liver, Hepatoma |
| M20 | CRL-2038 | M-1 | Tg(SV40)Bri/7 | Normal renal tissue, SV-40 transfected |
| M21 | CRL-2065 | MLTC-1 | C57BL/6 | Testis, Leydig cell tumor |
| M22 | CRL-2113 | E.G7-OVA | C57BL/6N | Blood, Lymphoma |
| M23 | CRL-2116 | JC | BALB/cRos | Mammary adenocarcinoma |
| M24 | CRL-2123 | mIMCD-3 | Tg(SV40)Bri/7 | Kidney medullary duct, SV-40 transfected |
| M25 | CRL-2148 | WEHI-13VAR | BALB/c | Fibrosarcoma |
| M26 | CRL-2278 | RAW 264.7 gamma NO(-) | BALB/c | Macrophage, virus transformed |
| M27 | CRL-2279 | MS1 (Mile Sven 1) | C57BL/6 | Pancreas/islet of Langerhans, SV-40 transfected |
| M28 | CRL-2469 | EOC 20 | C3H/HeJ | Brain |
| M29 | CRL-2539 | 4T1 | BALB/cfC3H | Breast, Mammary tumor (stage IV) |
| M30 | CRL-2623 | W-20-17 | W++ | Bone marrow, Stroma |
| M31 | CRL-2638 | CT26.WT | BALB/c | Colon carcinoma |
| M32 | CRL-2639 | CT26.CL25 | BALB/c | Colon carcinoma |
| M33 | CRL-2755 | EMT6 | BALB/cCrgl | Breast, Mammary carcinoma |
| M34 | CRL-2947 | Renca | BALB/cCr | Kidney, Renal adenocarcinoma |
| M35 | CRL-6322 | B16-F0 | C57BL/6J | Skin, Melanoma |
| M36 | CRL-6323 | B16-F1 | C57BL/6J | Skin, Melanoma |
| M37 | TIB-160 | YAC-1 | A/Sn | Lymphoma, MLV |
| M38 | TIB-192 | M1 | SL | Lymphocyte, Myeloid leukemia |
| M39 | TIB-197 | BCL1 clone 5B1b | BALB/c | Leukemia/Lymphoma |
| M40 | TIB-208 | A20 | BALB/cAnN | B lymphocyte, Reticulum cell sarcoma |
| M41 | TIB-214 | CTLL-2 | C57BL/6 | Cytotoxic T lymphocyte |
| M42 | TIB-224 | D10.G4.1 | AKR/J | Lymph Node, Helper T lymphocyte |
| M43 | TIB-239 | 2E8 | BALB/c.xid | Bone marrow |
| M44 | TIB-39 | EL4 | C57BL/6N | T lymphocyte, Lymphoma |
| M45 | TIB-49 | C1498 | C57BL/6J | Lymphocyte, Acute myeloid leukemia |
| M46 | TIB-6 | J558 | BALB/c | B lymphocyte, Plasmacytoma/myeloma |
| M47 | TIB-64 | P815 | DBA/2 | Mast cell, Mastocytoma |
| M48 | TIB-66 | Sarcoma 180 | Swiss Webster | Ascites, Sarcoma |
| M49 | TIB-68 | WEHI-3 | BALB/c | Peripheral blood, Leukemia |
| M50 | TIB-71 | RAW 264.7 | BALB/c | Ascites, AMLV |
| H1 | CRL-1486 | HEPM (Human) | Not applicable | Palatal mesenchyme |
*Moloney leukemia virus (MLV); Abelson murine leukemia virus (AMLV)
STR profile for Calibrant 1 (C1).
| STR Marker | Alleles |
|---|---|
| 18–3 | 16,19,21 |
| 4–2 | 16.3,19.3,20.3 |
| 11–1 | 19.3,20.3 |
| 6–7 | 12,15,16 |
| 19–2 | 12,13,14 |
| 1–2 | 13,15,18 |
| 7–1 | 26.2,28,29 |
| 1–1 | 11,14 |
| 3–2 | 13.1,14 |
| 8–1 | 14,15,16 |
| 2–1 | 9 |
| 15–3 | 20.3,22.3,23.3 |
| 6–4 | 15.3,18,18.3 |
| 11–2 | 15,15.3,18 |
| 17–2 | 15,16 |
| 12–1 | 15,16,18 |
| 5–5 | 13,16,17 |
| X-1 | 24,25,28 |
| 13–1 | 16.2,17,18 |
Mouse multiplex PCR assay.
| Marker | Species | Chr Loc. | Forward Primer (5'-3') | Reverse Primer (5'-3') | Final [Primer] in 20μL (μM) |
|---|---|---|---|---|---|
| 18–3 | mouse | 18 | 150 | ||
| 4–2 | mouse | 4 | 200 | ||
| 11–1 | mouse | 11 | 150 | ||
| 6–7 | mouse | 6 | 200 | ||
| 19–2 | mouse | 19 | 200 | ||
| 1–2 | mouse | 1 | 225 | ||
| 7–1 | mouse | 7 | 200 | ||
| 1–1 | mouse | 1 | 150 | ||
| 3–2 | mouse | 3 | 200 | ||
| 8–1 | mouse | 8 | 200 | ||
| 2–1 | mouse | 2 | 125 | ||
| 15–3 | mouse | 15 | 100 | ||
| 6–4 | mouse | 6 | 200 | ||
| 11–2 | mouse | 11 | 200 | ||
| 17–2 | mouse | 17 | 200 | ||
| 12–1 | mouse | 12 | 200 | ||
| 5–5 | mouse | 5 | 250 | ||
| X-1 | mouse | X | 275 | ||
| 13–1 | mouse | 13 | 250 | ||
| D8S1106 | human | 8 | 200 | ||
| D4S2408 | human | 4 | 250 |